Unbalanced expression of HLA-A and -B antigens: A specific feature of cutaneous melanoma and other non-hemopoietic malignancies reverted by IFN-γ

International Journal of Cancer

Volumn 91, Issue 4, 2001, Pages 500-507

  Gasparollo, Aldo ^a,b   Coral, Sandra ^a   Ciullo, Marina ^a   Prisco, Antonella ^a   Cattarossi, Ilaria ^a   Sigalotti, Luca ^a   Altomonte, Maresa ^a   Guardiola, John ^a   Maio, Michele ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

Author keywords

Hemopoietic tumors; HLA class I antigens; IFN ; Melanoma; Solid tumors

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GAMMA INTERFERON; HLA A ANTIGEN; HLA B ANTIGEN; MESSENGER RNA; PROTEIN; RIBONUCLEASE;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; FLOW CYTOMETRY; GENE CONTROL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MELANOMA; MELANOMA CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SOLID TUMOR;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; AZACITIDINE; BASE SEQUENCE; CELLS, CULTURED; DNA, COMPLEMENTARY; DOWN-REGULATION; FLOW CYTOMETRY; HLA-A ANTIGENS; HLA-B ANTIGENS; HUMANS; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; MELANOMA; MOLECULAR SEQUENCE DATA; NEOPLASMS; PHENOTYPE; RECOMBINANT PROTEINS; RIBONUCLEASES; RNA, MESSENGER; SEQUENCE HOMOLOGY, NUCLEIC ACID; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0035865966     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1076>3.0.CO;2-I     Document Type: Article

References (22)

1. Genetic predetermination of quantitative expression of HLA antigens in platelets and mononuclear leukocytes
2. Low prevalence of selective human leukocyte antigen (HLA)-A and HLA-B epitope losses in early-passage tumor cell lines
3. Suppression of class I human histocompatibility leukocyte antigen by c-myc is locus specific
4. High frequency of allele-specific down-regulation of HLA class I expression in uveal melanoma cell lines
5. Repression of the minimal HLA-B promoter by c-myc and p53 occurs through independent mechanisms
6. Role of the interferon-stimulated response element in HLA-B downregulation in human melanoma cell lines
7. HLA-B down-regulation in human melanoma is mediated by sequences located downstream of the transcription-initiation site
8. Transactivation of classical and nonclassical HLA class I genes through the IFN-stimulated response element
9. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines
10. Antigen recognition by class I-restricted T lymphocytes
11. IFN-mediated differential regulation of the expression of HLA-B7 and HLA-A3 class I genes
12. Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2′-deoxycytidine (5-AZA-CdR)
13. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells
14. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants
15. Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with b2m gene
16. Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity
17. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes
18. A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3
19. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1
20. The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles
21. Melanoma immunotherapy: New dreams or solid hopes?
22. The HLA crossroad in tumor immunology